Aldeyra Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M | -$56.2M |
| Cash from operations | -$33.3M | -$43.2M | -$30.3M | -$56.6M | -$42.6M |
| Capital expenditure | — | — | $0 | $16,317 | $7,806 |
| Free cash flow | — | — | -$30.3M | -$56.7M | -$42.6M |
| Total assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M |
| Total liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M |
Shares outstanding 60.3M · Free float 78.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.